MX2020011453A - Combinaciones para tratar el cancer. - Google Patents

Combinaciones para tratar el cancer.

Info

Publication number
MX2020011453A
MX2020011453A MX2020011453A MX2020011453A MX2020011453A MX 2020011453 A MX2020011453 A MX 2020011453A MX 2020011453 A MX2020011453 A MX 2020011453A MX 2020011453 A MX2020011453 A MX 2020011453A MX 2020011453 A MX2020011453 A MX 2020011453A
Authority
MX
Mexico
Prior art keywords
sup
treating cancer
combinations
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
MX2020011453A
Other languages
English (en)
Inventor
Scott Boiko
Justin Cidado
Lisa Drew
Theresa Proia
Martin Maryann San
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2020011453A publication Critical patent/MX2020011453A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se desvelan métodos de tratamiento del cáncer que comprenden administrar ácido 17-cloro-5,13,14,22-tetrametil-28-oxa-2,9-ditia- 5,6,12,13,22-pentaazaheptaciclo[27.7.1.14,7.011,15.016,21.020,24. 030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35- tridecaeno-23-carboxílico, una sal farmacéuticamente aceptable del mismo; y acalabrutinib, o una sal farmacéuticamente aceptable del mismo.
MX2020011453A 2018-04-30 2019-04-29 Combinaciones para tratar el cancer. MX2020011453A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862664356P 2018-04-30 2018-04-30
PCT/IB2019/053491 WO2019211721A1 (en) 2018-04-30 2019-04-29 Combinations for treating cancer

Publications (1)

Publication Number Publication Date
MX2020011453A true MX2020011453A (es) 2020-12-07

Family

ID=66794041

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020011453A MX2020011453A (es) 2018-04-30 2019-04-29 Combinaciones para tratar el cancer.

Country Status (14)

Country Link
US (1) US20210030718A1 (es)
EP (1) EP3787620A1 (es)
JP (1) JP2021522246A (es)
KR (1) KR20210005182A (es)
CN (1) CN112040944A (es)
AU (1) AU2019263026B2 (es)
BR (1) BR112020022020A2 (es)
CA (1) CA3097486A1 (es)
EA (1) EA202092540A1 (es)
MA (1) MA52499A (es)
MX (1) MX2020011453A (es)
SG (1) SG11202010528XA (es)
TW (1) TW202014184A (es)
WO (1) WO2019211721A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023501317A (ja) * 2019-11-04 2023-01-18 アストラゼネカ・アクチエボラーグ Ｂ細胞悪性腫瘍を処置するためのアカラブルチニブとカピバセルチブとの治療的組み合わせ
MX2022007474A (es) * 2019-12-18 2022-08-04 Zeno Man Inc Compuestos macrociclicos.
CN117651554A (zh) 2021-06-11 2024-03-05 吉利德科学公司 Mcl-1抑制剂与抗癌剂的组合
US11931424B2 (en) 2021-06-11 2024-03-19 Gilead Sciences, Inc. Combination MCL-1 inhibitors with anti-body drug conjugates

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2841886C (en) 2011-07-19 2016-08-16 Merck Sharp & Dohme B.V. 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors
CN106714909A (zh) * 2014-08-08 2017-05-24 药品循环有限责任公司 布鲁顿氏酪氨酸激酶抑制剂组合及其用途
AR108301A1 (es) * 2016-04-22 2018-08-08 Astrazeneca Ab Inhibidores de mcl-1 y métodos de uso de los mismos
CN107056786B (zh) * 2016-10-14 2019-05-07 苏州明锐医药科技有限公司 阿卡替尼的制备方法

Also Published As

Publication number Publication date
AU2019263026A1 (en) 2020-12-17
AU2019263026B2 (en) 2022-06-30
EA202092540A1 (ru) 2021-03-17
EP3787620A1 (en) 2021-03-10
BR112020022020A2 (pt) 2021-02-02
CN112040944A (zh) 2020-12-04
KR20210005182A (ko) 2021-01-13
SG11202010528XA (en) 2020-11-27
TW202014184A (zh) 2020-04-16
WO2019211721A1 (en) 2019-11-07
JP2021522246A (ja) 2021-08-30
MA52499A (fr) 2021-04-14
CA3097486A1 (en) 2019-11-07
US20210030718A1 (en) 2021-02-04

Similar Documents

Publication Publication Date Title
MX2020011453A (es) Combinaciones para tratar el cancer.
MX2019013954A (es) Inhibidores covalentes de kras.
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
MX2018000777A (es) Compuestos de quinazolina sustituido y su uso como inhibidores de proteinas kras, hras y/o nras mutantes g12c.
PH12016501394A1 (en) Compounds for treating patients with ros1 mutant cancer cells
MX2021005075A (es) Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion.
MX2020010369A (es) Particulas implantables y metodos relacionados.
MX2020013557A (es) Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y métodos de uso del mismo.
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
MX2018004309A (es) Terapias combinadas para tratar el cancer.
WO2016133903A3 (en) Combination therapy for cancer treatment
MX2021009439A (es) Derivados de imidazo [2,1-f] [1,2,4] triazin-4-amina como agonista de tlr7.
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
EP4364741A3 (en) Polymorphic form of tg02
MX2018015172A (es) Metodos para tratar cancer pancreatico.
MX2020010618A (es) Derivados de pirazolotriazolopiriminina como antagonista del receptor a2a.
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2021007247A (es) Derivados de rapamicina.
PH12020552274A1 (en) Formulations of an axl/mer inhibitor
JOP20220042A1 (ar) طرق لعلاج فرط فينيل ألانين الدم
MX2021012105A (es) Compuestos de pirrol.
MX2022005358A (es) Composiciones de copolímero de bloque sensibles al ph, micelas, y métodos de uso.
MX2021014523A (es) Metodos para tratar colangiocarcinoma.